Sera Prognostics, Inc. (SERA)
After hours:
| Previous close | 8.03 |
| Open | 8.15 |
| Bid | 8.40 x 200 |
| Ask | 8.50 x 200 |
| Day's range | 7.81 - 8.56 |
| 52-week range | 1.52 - 12.35 |
| Volume | |
| Avg. volume | 210,098 |
| Market cap | 275.272M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern
- PR Newswire
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.
- PR Newswire
SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today.
